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Abstract
The need for agents to lower body copper in Wilson's disease, a disease which results from copper toxicity has been
the driving force for the development of the effective anticopper drugs penicillamine, trientine, zinc, and now
tetrathiomolybdate (TM).  Because of its rapid action, potency, and safety, TM is proving to be a very effective drug
for initial treatment of acutely ill Wilson's disease patients. Beyond this, TM has antiangiogenic effects, because
many proangiogenic cytokines require normal levels of copper. This has led to use of TM in cancer, where it is gen-
erally effective in animal tumor models, and has shown efficacy in preliminary clinical studies. Most recently, it has
been found that TM has antifibrotic and antiinflammatory effects through inhibition of profibrotic and proinflam-
matory cytokines. 
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Introduction
Wilson’s disease [1-4], which produces liver and
brain damage due to copper accumulation and cop-
per toxicity, has been the major stimulus for the
identification of clinically useful anticopper drugs.
Walshe [5] was the first to discover an effective oral
drug, in penicillamine. Penicillamine was soon
found to have a large number of toxicities, and
Walshe [6] developed trientine as a substitute for
use in penicillamine intolerant patients. Trientine
shares some of penicillamine’s side effects, but
appears to be significantly less toxic. Both drugs act
as chelators, increasing urinary excretion of copper
sufficient to provide a negative copper balance in
Wilson’s disease patients.
The anticopper effects of zinc for potential use
in Wilson’s disease were discovered independently
by two groups, one in the Netherlands and one in
the U.S. Schouwink [7] was the first to use zinc in
Wilson’s disease, giving it to two patients who then
seemed to do well on this therapy. Schouwink’s
work appeared in his PhD thesis, but was never
published. His work was followed up by
Hoogenraad and his group in the Netherlands [8,9].
In the U.S., our group observed that zinc therapy
was consistently producing copper deficiency in
sickle cell anemia patients [10,11]. This led to clin-
ical trials of zinc in Wilson’s disease [12,13], ulti-
mately culminating in approval by the U.S. Food
and Drug Administration for maintenance therapy
in Wilson’s disease, in 1997.
While zinc is proving to be almost ideal for the
maintenance therapy of Wilson’s disease, it is
viewed as too slow-acting for initial treatment of
acutely ill patients. Penicillamine is fast acting, but
we have learned that it carriers a 50% risk of mak-
ing neurologically-presenting patients worse neu-
rologically [14]. The mechanism seems to be mobi-
lization of some of the hepatic copper into the
brain. Of the worsened patients, about 50% (one in
four of the original sample) never recover their
original function.
To fill this therapeutic void, we have developed
tetrathiomolybdate (TM), as a fast acting, very
potent, anticopper agent. In the remainder of this
review we will discuss the use of TM in Wilson’s
disease, and then go on to discuss its use as an
antiangiogenic, antifibrotic, and antiinflammatory
agent.
Early work on the development of
tetrathiomolybdate
The discovery of the anticopper effect of TM dates
back to observations in New Zealand and Australia,
where ruminants, but not non-ruminants, grazing on
certain pastures developed a disease later identified
as copper deficiency [15-17]. The soil of these pas-
tures had a high concentration of molybdenum.
Molybdenum fed to ruminants, but not when fed to
non-ruminants, was shown to cause copper deficien-
cy [18-20]. Then it was realized that the sulfur-rich
rumen was converting molybdenum to thiomolyb-
dates [21], and these compounds were found to have
anticopper activity in all animals, with the tetra-sul-
fur compound, TM, being the most potent [22-24].
Considerable experimental work with TM was
done in animals over the years. TM is a very potent
anticopper agent, and is quite toxic. However, all of
its side effects in animals are due to copper defi-
ciency, that is, copper supplementation prevents all
TM toxicity [24]. TM acts as an anticopper agent by
forming a tight tripartite complex with copper and
protein[22-25]. Given with food, TM complexes
food copper with food protein and prevents copper
absorption [26-29]. Given between meals, or par-
enterally, TM forms a tight complex with available
serum copper (often called free copper) and albu-
min, and renders the copper unavailable for cellular
uptake. This complex is metabolized in the liver
and the components excreted in the bile [30-32].
TM is life saving when given intravenously to cop-
per poisoned sheep, who usually die from acute
liver failure [33-35].
Tetrathiomolybdate for the therapy
of Wilson’s disease
Prior to our use of TM, it had been used in one or
two terminal Wilson’s disease patients in Australia,
and Walshe had tried it briefly in England for main-
tenance therapy in two patients who were intolerant
of both penicillamine and trientine [36]. Walshe
gave up on it when it produced a reversible anemia
in one of these patients.
To me, TM seemed ideal for initial therapy of the
neurologically-presenting patient, because of its
potency, fast action, and low toxicity in animal stud-
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ies. Although formal toxicity studies had not been
done, based on the rather extensive animal studies
which had been carried out, we received FDA appro-
val for use of TM for up to eight weeks in Wilson’s
patients presenting with neurological disease.
This study involved an eight week admission to
the General Clinical Research Center of the
University of Michigan, with weekly semi-quantita-
tive neurological and semi-quantitative speech
examinations. TM was given both with meals, most
often 20 mg three times daily, to block absorption of
food copper, and between meals, most often 20 mg
three times daily, to allow complexing of free cop-
per, serum albumin and TM. (A note of importance
for later cancer and other studies, serum copper is
not usable in TM treatment as a marker of copper
status, because the blood complex builds up, elevat-
ing serum copper). In an open label study now total-
ing 55 patients [26-29], TM has shown excellent
efficacy in protecting neurological function while
gaining control over copper toxicity in about two
weeks time. Two of the 55 patients did reach our cri-
teria for neurological worsening. We postulate that
in an occasional patient, events are in motion lead-
ing to additional neurological deterioration irrespec-
tive of the anticopper drug treatment. However, it
appears that penicillamine produces a drug-cat-
alyzed neurological worsening in about half of the
patients. Currently we are in the final stages of a
double blind trial comparing TM to trientine for ini-
tial therapy of the neurologically-presenting patient.
We have seen bone marrow suppression by TM
in about 11% of patients [26-29]. This is due to cop-
per deficiency in the bone marrow, and responds
quickly to dose reduction to half the standard dose
of 120 mg/day, or to a brief drug holiday. The other
side effect is a mild transaminitis to two or three
times baseline levels in 15% of patients [26-29],
again responsive to halving the dose. These side
effects have caused us to initiate a protocol in which
we are examining whether or not efficacy can be
retained and side effects minimized by using half
the daily dose (60 mg/day) for twice as long.
Tetrathiomolybdate copper-lowering
therapy for antiangiogenesis
Folkman has pioneered the concept that tumors
require angiogenesis for growth, and that since nor-
mal adult tissues do not require angiogenesis except
for wound healing and the menstrual cycle, angio-
genesis is a potential Achilles heel of cancer [37-
39]. In recent years the approach of antiangiogene-
sis for cancer therapy has seen great activity
[40,41]. Angiogenic factors, or their receptors, are
often targeted, or angiogenic inhibitors are used.
This field remains quite promising, although it is
clear that it also has not held up to some of the early
expectations [42-44]. The likely problem lies in the
very large number of angiogenic promoters.
Inhibition of one promoter or its receptor may lead
to only temporary effects, because the tumor, par-
ticularly if it is advanced, with large numbers of
cancer cells, will find ways, such as by mutation, to
bypass the blocked system and use other angiogenic
factors.
Literature dating back to the 1980s has dealt
with the role of copper in angiogenesis. Early work
used the rabbit cornea model. Copper, or molecules
containing copper such as ceruloplasmin, were
shown to be angiogenic in this model [45,46]. Even
more interesting, if rabbits were made modestly
copper deficient with a combination of low copper
diet and penicillamine therapy, a known angiogenic
stimulus placed in the eye, such as prostaglandin
E1, became much less angiogenic [47]. This sug-
gested that a normal level of copper was required
for active angiogenesis.
Brem and colleagues [48,49] used this copper
deficient model to show that tumors implanted in
the brains of rabbits or rats grew much more slow-
ly and had no tendency to invade normal tissues in
copper deficient animals compared to normal con-
trols. However, there was a lack of survival advan-
tage, apparently due to equivalent brain stem herni-
ation in treated and control animals, and this work
was not pursued.
The development of TM for Wilson’s disease
gave our group an opportunity to enter the antian-
giogenesis field with a new, potent, fast-acting, rel-
atively non-toxic, anticopper agent. Initial work
was positive, in a mouse model injected with MCA
205 sarcoma cells (Brewer, unpublished results).
The tumor grew more slowly in the TM treated ani-
mals. This work also led to the successful develop-
ment of serum ceruloplasmin (Cp) levels as a sur-
rogate marker of copper status when TM is used as
therapy. Serum copper can’t be used because it
builds up in an albumin, copper, TM complex in the
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blood. Cp is made by the liver at a rate dependent
upon the availability of copper to incorporate into
the protein [50]. At that point, I teamed up with an
oncologist, Dr. Sofia Merajver, for further work.
She designed a study in the HER2/neu transgenic
mouse which was strongly positive [51,52]. These
mice are genetically programmed to develop breast
cancer during the first year of life. At 100 days of
life, 15 mice began daily treatment with TM by
gavage, while 22 received an equivalent amount of
vehicle (water). By 218 days, 15 of 22 control mice
had developed grossly visible, often multiple,
mammary tumors. None of the 15 TM treated ani-
mals had developed visible tumors. At this point the
effect was highly significant statistically, and the
experiment was stopped [52]. Upon dissection and
microscopic examination, TM treated animals were
found to have small, avascular, clusters of tumor
cells. Therapy was stopped in a few TM treated
mice and they all quickly developed obvious
tumors.
Positive studies have now been done in other
rodent models, including head and neck cancer,
both under the tongue and in the flank [53], inflam-
matory breast cancer [52], lung cancer [54], and
prostate cancer [55]. A study has also been done in
13 pet dogs presenting with a variety of advanced
and metastatic cancers [56]. Nine of these dogs
were evaluable, meaning that the Cp levels were in
the target range at least one month before progres-
sion caused the dog to be withdrawn. Three of the
nine dogs had stable disease for several months, and
a fourth had a partial response in reduction of lung
metastases size, and elimination of hypertrophic
osteopathy that had resulted from the malignancy.
This dog, and one other, had rather remarkable dis-
ease stabilization compared to what would have
been expected without therapy.
Our initial human clinical study involved a
phase I/II study in 18 patients with a variety of
advanced and metastatic cancers [57]. With the
doses of TM we used it takes 3-4 weeks to get the
Cp into the target range of 5-15 mg/dl (normal is
20-35, but the values are often quite increased in
metastatic cancer, because Cp is an acute phase
reactant). We viewed patients as evaluable after the
Cp was in the target range for two months. Many
patients withdrew before that because of unaccept-
able progression. In the 6 evaluable patients of the
18 total patients reported, disease stabilization for
some period of months was seen in all. The study
has since been expanded to 42 patients, of whom 18
were evaluable (Merajver and Brewer, unpublished
results). In these 18 patients, freedom from pro-
gression averaged 11 months, against an expected
of about two months in this type of patient. Results
were exceptional in three of these patients. One a
renal cell cancer patient, had freedom from pro-
gression for 18 months, and a metastatic breast can-
cer patient went almost 36 months before there was
progression in one lymph node. A third patient, with
metastatic chondrosarcoma, is out now four years
without progression. The quality of life of these
patients was deteriorating at a significant pace prior
to therapy, and then leveled off during therapy.
At present a series of phase II studies of
advanced and metastatic cancers is underway, and it
is too early to know any of the findings. Studies of
combination therapy of TM with other modalities
are just being started or being planned.
The mechanism of TM action is probably inhibi-
tion of pro-angiogenic cytokines through various
mechanisms. One mechanism is probably copper
dependence for activity of various cytokines. Table
1 provides a list of cytokines thought to be depen-
dent upon copper. A second mechanism, also listed
in Table 1, involves inhibition of NFκB, which
potentially results in reduced transcription of a
large number of angiogenic cytokines [52]. These
mechanisms, collectively, may result in a somewhat
more global inhibition of angiogenesis than that
obtained with other therapies currently under trial.
My crystal ball on TM and cancer is that it will
have some efficacy as sole therapy for advanced
cancer, with an average 10-11 months freedom
from progression, with some, perhaps 20% excel-
lent stabilization and occasional, perhaps 5-10%,
remarkable remission. I’m basing these guessti-
mates on both the canine and the human studies.
However, the usual course will be that these large
tumor masses will find a way to progress. I believe
the real potential of TM is exemplified by the
HER2/neu mouse study. That is, I think there is
great potential for chemoprevention in high risk
patients and for inhibiting the growth of
micrometastatic disease. A corollary to that would
be to use TM to prevent regrowth in conjunction
with agents such as chemotherapy, radiation, or
surgery that greatly debulk the tumor and make
remaining tumor remnants as small as possible.
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The toxicity of TM in cancer patients has been
limited to bone marrow suppression in conjunction
with overtreatment and too severe copper deficien-
cy [57,65], and occasional complaints of sulfur
smelling burps. The bone marrow suppression has
been a rather benign side effect, responding quick-
ly to dose reduction or drug holiday. It occurs fre-
quently when the Cp is below 5 mg/dl, fairly often
between 5 and 10, uncommonly between 10 and 15,
and essentially not at all over 15. The transaminitis
we have observed in Wilson’s disease has not been
seen in cancer patients or in animal studies.
Besides cancer, other diseases of neovascular-
ization include wet-type macular degeneration, dia-
betic retinopathy, rheumatoid arthritis, and psoriasis
[66]. A small clinical trial of TM in 10 patients with
wet-type macular degeneration was negative in that
the progression of the disease in terms of loss of
sight was not arrested, and choroidal neovascular-
ization continued (Vine and Brewer, unpublished
results).
However, the choroidal and retinal vasculatures
are different, so we have initiated work on a rodent
model of retinopathy. There is not an ideal model of
diabetic retinopathy, so we have used the retinopa-
thy of prematurity for initial studies [67]. In this
model, newborn mice are exposed to 75% oxygen
for five days, and then to room air. In the relative
hypoxia of room air, they have a large increase of
vascular endothelial growth factor (VEGF), the
major angiogenic cytokine in the eye, within 24
hours, followed by a retinopathy. TM treatment,
begun before exposure to room air, greatly inhibits
both the VEGF increase and the neovascularization
in the retina (Elner and Brewer, unpublished
results). This work lends hope that TM will be an
effective therapy for diabetic retinopathy. 
Tetrathiomolybdate copper-lowering
therapy for antifibrosis and
antiinflammation
The pathway of fibrosis involves transforming
growth factor beta (TGFβ), which stimulates con-
nective tissue growth factor (CTGF) which acti-
vates a number of collagen genes and other genes
contributing to fibrosis [68,69]. This pathway is
physiologically important, for example in wound
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Cytokines which may be copper dependent
Cytokine or Factor References
Vascular endothelial growth factor (VEGF) [40,58]
Fibroblastic growth factor (FGF) [59,60]
Angiotropin [61]
Angiogenin [62]




NFκB Master Switch Inhibition [52]
Table 1 Possible copper-dependent mechanisms for TM antiangiogenesis
repair. However, it becomes dysregulated and over-
active after injury in a large number of different
organs [68].
In looking at this pathway, it seemed that some
of the cytokines had a good chance of being copper
dependent in the same manner as many of the
angiogenic cytokines. For example SPARC, one of
the copper dependent cytokines listed in Table 1, is
one stimulator of TGFβ[70]. CTGF itself is very
cysteine rich, suggesting copper dependence.
To test this hypothesis, I collaborated with Sem
Phan, a pathologist at the University of Michigan,
who had the bleomycin mouse model for pul-
monary fibrosis [71] set up and running. In this
model, bleomycin placed in the trachea causes lung
injury, with a major inflammatory response, pri-
marily stimulated by tumor necrosis factor alpha
(TNFα), peaking at seven days, followed by a
strong fibrotic response easily measurable at 21
days when the experiment is terminated.
Meanwhile the animals lose a great deal of weight
as part of the illness.
TM therapy is able to almost completely abro-
gate these bleomycin induced injuries [72,73].
Fibrosis is measured by an increase in hydroxypro-
line, a major amino acid constituent of collagen, in
the lung. This level doubles in bleomycin control
animals, but was not different in TM treated
bleomycin animals than in saline controls.
Histologically, TM protected against the fibrotic
and inflammatory changes induced by bleomycin.
TM completely protected against bleomycin
induced weight loss. TM could be started after the
inflammatory peak, and still protect against much
of the fibrosis, indicating it is probably inhibiting
both fibrotic and inflammatory responses [72,73].
With this positive lung data in hand, with Fred
Askari, a hepatologist at the University of
Michigan, we have moved to testing TM protective
effects in liver injury [74]. Intravenous injection of
concanavalin A (con A) in mice produces a serum
transaminase response. TM therapy completely pre-
vented an elevation of amino leucine transaminase
(ALT) from con A injection. After four weeks of
con A injections initiation of TM therapy returned
previously elevated ALT levels to normal in spite of
continued con A injections. After 10 weeks of con A
injections control mice showed inflammatory
changes and early fibrosis in their livers, while TM
treated mice were histologically normal [74].
How and why copper-lowering
therapy might work
As discussed earlier, it appears that the antiangio-
genic effect of TM is through inhibition of multiple
angiogenic cytokines, probably through multiple
mechanisms. Similarly, the antifibrotic and antiin-
flammatory effects of copper-lowering by TM
probably results from inhibition of key cytokines,
such as TGFβ, TNFα, and interleukin 1β (IL1β).
SPARC, which activates TGFβ in the fibrotic path-
way, is known to be copper dependent.
Thus it seems likely that a large number of
angiogenic, growth promoting, inflammatory, and
fibrotic cytokines are in some manner inhibited by
copper-lowering therapy with TM. A reasonable
question to ask is, what is the physiological ratio-
nale for this dependence on copper levels for so
much cytokine signaling? Copper is an essential
trace element, but so are many other metals such as
zinc, iron, calcium, magnesium, manganese, and so
forth, yet these are not used in this general manner
for signaling or modulating cytokine activity. We
have previously speculated that the answer may be
in environmental variability in copper bioavailabil-
ity [65,75]. There is evidence for this variability in
soils themselves, as well as the susceptibility of
grazing animals to frequent problems with copper
deficiency [75]. Our hypothesis is that primitive
organisms developed signaling mechanisms for
growth in the presence of adequate copper, and that
these signals were shut off when copper was scarce,
allowing survival but not growth. We postulate that
these copper dependent signals have been retained
in the evolution of higher organisms [75].
Potential future outlook and what remains
to be done
My current views on where TM will eventually fit in
cancer therapy is as follows. Used as sole therapy, it
has the potential to be very good as a prophylactic
agent in high risk patients for cancer, as long as the
safety profile remains as good as it appears to be cur-
rently. It also should be excellent for prevention of
growth of micrometastatic disease, as modeled by the
HER2/neu transgenic mouse mammary cancer study.
For example, if a primary tumor is removed by
surgery, but there is likely to be micrometastatic dis-
16
ease elsewhere, TM may be excellent at preventing
growth of these small pockets of disease. In more
advanced and macroscopically metastatic cancer,
TM’s role will probably best fit as an adjunctive ther-
apy, in combination with other modalities. For exam-
ple, if the tumor masses can be greatly reduced by
another therapy, TM may help in preventing
regrowth. In some types of tumors, it may be very
effective as sole therapy.
Based on one pilot clinical trial, it seems unlikely
that TM will be effective in macular degeneration. On
the other hand, a positive retinopathy animal model
study predicts TM may be helpful therapy in diabetic
retinopathy. We have no basis for prediction whether
TM will be useful in other diseases where neovascu-
larization is a factor, such as psoriasis and rheumatoid
arthritis. However, I’ll comment further on rheuma-
toid arthritis below.
My current views on where TM will eventually fit
in antifibrotic and antiinflammatory therapy are very
speculative at present because so far we only have
limited animal data. This animal data is very positive,
involves multiple organs, and includes evidence of
inhibition of key cytokines, such as TNFα and TGFβ.
Since the inflammatory and fibrotic dysregulations
that lead to inflammatory and fibrotic diseases gener-
ally use the same cytokine systems, it seems possible
that TM will be effective against these diseases in
most organs. Similarly, since these systems are com-
mon between rodents and humans, it is quite possible
that strong therapeutic effects in a large variety of dis-
eases will also be seen in patients.
Thus, a rosy scenario could be suggested (or fan-
tasized!) that fibrotic diseases such as idiopathic pul-
monary fibrosis, cirrhosis, renal fibrosis, scleroderma,
graft rejection, restenosis, etc could be effectively
treated and progression halted, possibly even with
reversal. As part of that, for now fantasy, it is con-
ceivable that dysregulated inflammation could be bet-
ter and more safely treated than with steroids. On the
other hand, TM may be ineffective for fibrosis and
inflammation in the human. We’ll have to wait and
see.
Which brings us to the last topic, what do we have
to do now? I believe the foregoing paragraphs in this
section lay this out rather clearly. In cancer, we need
to evaluate clinical effectiveness as sole therapy in a
wide variety of tumor types, to see if there are some
which are very susceptible. We need to see if TM is
effective in preventing growth of micrometastases. If
this is positive, and the toxicity profile remains low,
chemoprevention trials in high-risk cancer patients
should be started. In situations of likely remaining
micrometastatic disease, for example after surgical
removal of a primary, the capability of TM to prevent
growth of these metastases needs to be tested. Finally,
combination therapies with TM where part of the
combination, such as chemotherapy, strongly
“debulks” the tumor need to be evaluated for TM’s
ability to stabilize the remaining tumors’ growth. On
a related topic, it would be useful to explore the
effects of TM in lymphoma and leukemia. While
these are not solid tumors of course, and thus are not
dependent upon angiogenesis, they may very well be
under the positive influence of some of the growth
factors we know TM inhibits, and TM therapy might
very well have efficacy.
In other diseases of neovascularization, such as
diabetic retinopathy, psoriasis, and rheumatoid arthri-
tis, it would seem worthwhile to do pilot type TM
clinical trials.
In diseases of fibrosis and inflammation, clinical
trials should be carried out where animal model work,
or other types of data, suggest a possible positive
result. For example, given the positive bleomycin ani-
mal work, we are planning a clinical trial of TM in
idiopathic pulmonary fibrosis. As another example, as
additional animal model liver work accumulates indi-
cating protection of the liver from inflammation and
fibrosis, we will consider a clinical trial in a human
disease of liver injury progressing to cirrhosis.
Rheumatoid arthritis deserves special consideration
because it is both a disease of angiogenesis [39] and
of inflammation, with TNFα playing a major role in
the latter [76]. Thus, a clinical trial in this disease
should certainly go forward.
Besides these clinical protocols evaluating the
range of efficacy of TM there is need for work to
define how to use TM in the most effective manner,
and what some of the long range safety issues are. In
terms of the use of TM, we lack information on how
low the ceruloplasmin need be in patients for optimal
results in terms of efficacy against various types of
cancer, versus the risks of overtreatment toxicity.
Similarly, we need information on the relative effec-
tiveness of with meal dosing vs. away from food dos-
ing in terms of effect on copper levels. Perhaps once-
a-day dosing, as we do in animals, would be just as
effective as the more complicated current human dose
regimen. Obviously, more information on the mecha-
17
J.Cell.Mol.Med. Vol 7, No 1, 2003
nism of antiangiogenesis would be useful. Knowing
the total pattern of proangiogenic suppression by TM
would allow plans to combine TM with other antian-
giogenic agents that suppress factors not affected by
TM.
A formal toxicity study on TM is being carried out
by the National Cancer Institute RAID program. The
study is almost done, and there have been no unex-
pected toxicities. However, some answers about long
term side effects will probably come only from
patients, and planning should begin for getting these
answers. For example, there is no evidence of a
molybdenum storage disease, but it would be useful
to do molybdenum balance studies to show that dur-
ing long-term TM therapy, molybdenum is in neutral
balance. Since copper deficiency has a known effect
on bone [77,78], particularly early in life, it would be
useful to do bone density studies during long-term
treatment. Copper deficiency has been implicated in
lowering certain immune functions [79-81], and it
would be good to study various immune functions
during long-term treatment. On occasion copper defi-
ciency has been claimed to affect the heart [79]. We
have not seen this in our patients but perhaps a larger,
more through study needs doing. Low copper levels
are part of a hypothesis by Klevay [82] that claims
that a high zinc/copper ratio is atherogenic by virtue
of elevating total cholesterol. We have not seen such
a result in our patients so far, but perhaps it deserves
further study in patients on long term TM therapy.
The effects of lowering copper levels on wound
healing needs more detailed evaluation. We know that
lysyl oxidase and other cellular enzymes are not
affected by the level of copper deficiency we induce
(unpublished results), but major wounds presumably
require some of the angiogenic and growth factor
cytokine signaling we know we are inhibiting with
TM. Therefore, currently we stop TM therapy prior to
major surgery. However, we know minor surgery,
tooth extractions, minor cuts, etc all heal quite nicely
while TM therapy is continued. It would be useful to
determine under what conditions TM therapy should
be temporarily stopped.
We know that copper is required for growth, there-
fore we have not used TM therapy in children (other
than for Wilson’s disease). However, children have
cancers that might be very susceptible to copper low-
ering therapy. The conditions under which TM can be
used in children, with minimal effects on growth,
should be explored.
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